Pesquisa de referências

The Histocompatibility antigen in asbestos related disease

<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
  <record>
    <leader>00000nab a2200000 i 4500</leader>
    <controlfield tag="001">MAP20071017128</controlfield>
    <controlfield tag="003">MAP</controlfield>
    <controlfield tag="005">20080418114932.0</controlfield>
    <controlfield tag="007">hzruuu---uuuu</controlfield>
    <controlfield tag="008">940203e19921201gbr||||    | |00010|eng d</controlfield>
    <datafield tag="035" ind1=" " ind2=" ">
      <subfield code="a">6800003051</subfield>
    </datafield>
    <datafield tag="040" ind1=" " ind2=" ">
      <subfield code="a">MAP</subfield>
      <subfield code="b">spa</subfield>
    </datafield>
    <datafield tag="084" ind1=" " ind2=" ">
      <subfield code="a">873</subfield>
    </datafield>
    <datafield tag="245" ind1="1" ind2="4">
      <subfield code="a">The Histocompatibility antigen in asbestos related disease</subfield>
      <subfield code="c">N. Al Jarad... [et al.]</subfield>
    </datafield>
    <datafield tag="520" ind1=" " ind2=" ">
      <subfield code="a">It has been recognised that for a given cumulative exposure to asbestos dust, only a fraction of the exposed workers developed one or more of the asbestos related diseases (benign pleural disease, asbestosis, mesothelioma, and lung cancer). In this study it was investigated class I and class II human leucocyte antigen (HLA) in patients with different types of asbestos related disease and compared prevalences of HLAs between different groups using the data obtained in this and previously published studies</subfield>
    </datafield>
    <datafield tag="650" ind1="1" ind2="1">
      <subfield code="0">MAPA20080576615</subfield>
      <subfield code="a">Medicina laboral</subfield>
    </datafield>
    <datafield tag="650" ind1="1" ind2="1">
      <subfield code="0">MAPA20080619480</subfield>
      <subfield code="a">Enfermedades profesionales</subfield>
    </datafield>
    <datafield tag="650" ind1="1" ind2="1">
      <subfield code="0">MAPA20080610579</subfield>
      <subfield code="a">Enfermedades pulmonares</subfield>
    </datafield>
    <datafield tag="650" ind1="1" ind2="1">
      <subfield code="0">MAPA20080558932</subfield>
      <subfield code="a">Inmunología</subfield>
    </datafield>
    <datafield tag="650" ind1="1" ind2="1">
      <subfield code="0">MAPA20080605278</subfield>
      <subfield code="a">Contaminantes químicos</subfield>
    </datafield>
    <datafield tag="650" ind1="1" ind2="1">
      <subfield code="0">MAPA20080542832</subfield>
      <subfield code="a">Amianto</subfield>
    </datafield>
    <datafield tag="700" ind1="1" ind2=" ">
      <subfield code="0">MAPA20080036201</subfield>
      <subfield code="a">Al Jarad, N.</subfield>
    </datafield>
    <datafield tag="740" ind1="0" ind2=" ">
      <subfield code="a">British journal of industrial medicine</subfield>
    </datafield>
    <datafield tag="773" ind1="0" ind2=" ">
      <subfield code="t">British journal of industrial medicine</subfield>
      <subfield code="d">London and Margate</subfield>
      <subfield code="g">nº 12, December 1992 ; p. 826-831</subfield>
    </datafield>
  </record>
</collection>